Skip to content

Drug interactions

Glasdegib + Lorlatinib

Severity: Moderate

Glasdegib and Lorlatinib: moderate interaction.

Last updated

For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.

Summary

Lorlatinib induces CYP3A and may lower glasdegib exposure, potentially reducing efficacy in AML. Glasdegib labeling cautions against strong CYP3A inducers, and lorlatinib's effect is likely weaker to moderate.

What this interaction means in plain words

Glasdegib and Lorlatinib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.

Glasdegib belongs to Oncology; Lorlatinib belongs to Oncology.

Evidence level: Low

Why it happens

Lorlatinib induces CYP3A4, increasing glasdegib clearance.

What to do

Avoid if possible. If combined, monitor disease response and consider dose adjustment per glasdegib labeling.

What to ask your pharmacist

  • Should I take them at different times of day?
  • Does the dose of either medicine need to change?
  • Is there anything I should avoid, such as alcohol or certain foods, while on both?

Bring a full list of your medicines, including over-the-counter products, supplements and herbal remedies, to every pharmacy visit.

Pro+ members

Unlock the full page

Create an account and start a Pro+ trial to unlock the full management advice for Glasdegib and Lorlatinib, the additional notes, the evidence detail and the whole-prescription interaction checker.

  • Full clinical management advice
  • Additional notes
  • Evidence detail
  • Interaction checker for a whole prescription

Try Pro+ free for 14 days on the web. No card needed.

Frequently asked questions

Can I take Glasdegib with Lorlatinib?

MediHelp rates the interaction as moderate. Glasdegib and Lorlatinib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Lorlatinib induces CYP3A and may lower glasdegib exposure, potentially reducing efficacy in AML. Glasdegib labeling cautions against strong CYP3A inducers, and lorlatinib's effect is likely weaker to moderate.

How serious is the interaction between Glasdegib and Lorlatinib?

MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid if possible. If combined, monitor disease response and consider dose adjustment per glasdegib labeling.

What other medicines interact with Lorlatinib?

MediHelp also lists interactions of Lorlatinib with, for example, Amobarbital, Apalutamide, Butabarbital. The full list is on the Lorlatinib page.

Full monographs, dosing and an interaction checker in the MediHelp app

Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.

Browse A–Z · Drug interactions

Get the app Sign in